Status:
TERMINATED
Novel Quantitative MRI for Axial Spondyloarthritis
Lead Sponsor:
The Cleveland Clinic
Collaborating Sponsors:
University of California, San Francisco
UCB PHARMA Inc. (US)
Conditions:
Spondylitis, Ankylosing
Eligibility:
All Genders
18+ years
Brief Summary
This proposal aims to develop novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity ...
Detailed Description
There is a critical and unmet clinical need for non-invasive techniques that provide early diagnosis as well as reliable and sensitive evaluations of ongoing disease activity and treatment response in...
Eligibility Criteria
Inclusion
- Active AS meeting the modified New York criteria
- BASDAI ≥ 4
- Elevated C-Reactive Protein
- ≥ 18 years old
- Initiation of TNFi treatment with CZP
Exclusion
- Previous treatment with more than one biologics
- Biologic treatment within six-months (no more than 20% of group (n=4) for patients with previous biologic treatment)
- Non-response to previous anti TNF treatment
- Fibromyalgia or other reasons for back pain
- Pregnant patients
- Patients on \> 10mg of Prednisone per day
Key Trial Info
Start Date :
January 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2021
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03778515
Start Date
January 15 2020
End Date
July 31 2021
Last Update
August 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143